Acoramidis significantly reduced all-cause mortality in both wild-type and variant amyloid cardiomyopathy through 42 months of the ATTRibute-CM study. The study demonstrated consistent efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback